Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding

China
Multiple pharma companies lost bids for established medicines under a procurement program in China. (Getty Images)

Several pharma giants—including Merck, Novartis, Eli Lilly and Pfizer—have just lost procurement deals in China under the country's new bidding system.

The drugmakers lost out to domestic producers, which in some cases undercut prices for established medicines by more than 90%, according to Jiemian. Among the drugs to lose contracts were Eli Lilly schizophrenia medicine Zyprexa and Pfizer’s Viagra, the publication said.

This week's bidding in Shanghai was the third round under a procurement program launched in 2018 aimed at saving billions of dollars. On Thursday, domestic and global companies bid for contracts on 56 medicines. 

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

RELATED: Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program 

Initially, the program focused on purchasing medicines for 11 cities in China. It has since expanded nationwide, threatening an important market for many Big Pharma players. 

Companies such as AstraZeneca, Sanofi and Eli Lilly have managed to keep business under the aggressive procurement program, but they had to live with major discounts. 

The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Research analyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines.

RELATED: Is Pfizer's established drugs' decline in China the 'canary in the coalmine?' 

It’s not a completely unforeseen shift, though. Pfizer’s established drugs business started showing a decline in China back in April 2019. At the time, Wolfe Research analyst Tim Anderson wondered whether the decline was the “canary in the coalmine” for the rest of the industry, which has been relying on the lucrative China market for revenue growth.

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.